IRB Quality Concerns Take Center Stage After FDA Clamps Down On Coast

Quality has moved up in importance as a criterion for selecting an institutional review board following an April 14 FDA warning letter to Coast IRB and the company's agreement to halt enrollment in clinical studies it monitors